ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Bharat Parenterals intimated that its Board will meet on 29 September 2026 to consider a preferential equity issue. The agenda item is proposed, not yet approved, with no amount disclosed.
Bharat Parenterals Limited has re-appointed Mr. Hemang Jayendrabhai Shah as Executive Director for a 5-year term effective July 2, 2026.
Bharat Parenterals Limited held its 33rd Annual General Meeting on September 19, 2026. The proceedings covered the adoption of financial statements and various resolutions.
Bharat Parenterals Limited has fixed September 12, 2026, as the record date to determine shareholder eligibility for the dividend for FY 2025-26.
Bharat Parenterals Limited has submitted its Annual Report for the financial year 2025-26. The report includes the notice for the 33rd Annual General Meeting.
Bharat Parenterals Limited has scheduled its 33rd Annual General Meeting on September 19, 2026, to discuss financial results, dividend declaration, and director reappointments.
Bharat Parenterals Limited shares have been admitted to trade on the National Stock Exchange under the 'Permitted to Trade' category effective August 17, 2026.
Bharat Parenterals is upgrading its subsidiary Varenyam Biolifesciences' Savli facility for biologics and biosimilars. This expansion involves a revised Phase 1 capital expenditure of ₹300 Crore.